XTL Biopharmaceuticals (XTLB) versus Its Peers Financial Survey

XTL Biopharmaceuticals (NASDAQ:XTLB) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare XTL Biopharmaceuticals to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, earnings, valuation, dividends and risk.

Profitability

This table compares XTL Biopharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
XTL Biopharmaceuticals Competitors	-12,357.18%	-197.96%	-30.56%

Risk & Volatility

XTL Biopharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals’ competitors have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Institutional and Insider Ownership

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares XTL Biopharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	-$6.97 million	-2.42
XTL Biopharmaceuticals Competitors	$716.53 million	$12.10 million	-15.00

XTL Biopharmaceuticals’ competitors have higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and target prices for XTL Biopharmaceuticals and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
XTL Biopharmaceuticals Competitors	9834	15121	45433	1587	2.54

As a group, “Biotechnology” companies have a potential upside of 102.62%. Given XTL Biopharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts plainly believe XTL Biopharmaceuticals has less favorable growth aspects than its competitors.

Summary

XTL Biopharmaceuticals competitors beat XTL Biopharmaceuticals on 7 of the 13 factors compared.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.